Summary:
- Phase III clinical trial results indicate that a personalized mRNA cancer vaccine, when administered alongside standard immunotherapy (pembrolizumab), significantly reduces the risk of recurrence or death in patients with high-risk stage III/IV melanoma.
- The study represents a major advancement in precision oncology, demonstrating the efficacy of utilizing neoantigen-specific T-cell responses to target malignant cells while sparing healthy tissue.